Skip to main content
Livermore
Livermore
ZHEN

Zenas BioPharma, Inc.

ZBIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001953926

No open-market purchases or sales by Zenas BioPharma, Inc. insiders were filed in the last 90 days; 144 institutions reported holding it in 13F filings for Q2 2026, worth $1.55B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Zenas BioPharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Zenas BioPharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Zenas BioPharma, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Oliger Christy J.Director–Sep 2, 20261
Moulder Leon O JrSee Remarks96,928IndirectJun 17, 20267
Enright Patrick GDirector11,990Jun 17, 20262
Farmer Joseph LSee Remarks974Jun 17, 20261
Allen Patricia LDirector19,860Jun 17, 20262
Nunn Jason RaleighDirector1,173,395IndirectJun 17, 20262
Orloff John JDirector–Jun 17, 20261
Lu HongboDirector426,736IndirectJun 17, 20265
von Moltke LisaSee Remarks–Jun 17, 20261
Fox Jennifer A.See Remarks1,592Jun 17, 20261
Boylan James PDirector–Jun 17, 20261
Harwin Peter EvanDirector2,359,025IndirectApr 1, 20262
Fairmount Healthcare Fund II L.P.Director2,359,025IndirectApr 1, 20262
Fairmount Funds Management LLCDirector2,359,025IndirectApr 1, 20262
Kiselak TomasDirector2,359,025IndirectApr 1, 20262
George Simeon10% Owner1,917,895IndirectOct 14, 20251
Sr One Capital Management, LLC10% Owner1,917,895IndirectOct 14, 20251
Oliveira OrlandoSee Remarks–Jun 12, 20250
Xiao TingDirector10,000Apr 28, 20250
Enavate Sciences GP, LLC10% Owner3,761,359IndirectSep 18, 20240
Zebra Aggregator, LP10% Owner3,761,359IndirectSep 18, 20240
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.10% Owner801,624Sep 18, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 18, 2026 (view filing)May 18Same dayMoulder Leon O JrChief Executive OfficerPPurchase+60.0K$16.88+$1.01M+162.5%96.9K after
Apr 29, 2026 (view filing)Apr 28-291 dayMoulder Leon O JrChief Executive OfficerPPurchase+60.0K$17.79+$1.07M+3.5%1.79M after2 lots
Apr 2, 2026 (view filing)Mar 312 daysLu HongboDirectorPPurchase+3.77K$18.63+$70.2K+0.9%426.7K after
Apr 1, 2026 (view filing)4:30 PM ETMar 311 dayHarwin Peter Evan and 3 othersDirectorPPurchase+150.0K$20.00+$3.00M+6.8%2.36M after
Mar 31, 2026 (view filing)Mar 30-311 dayMoulder Leon O JrChief Executive OfficerPPurchase+54.0K$18.91+$1.02M+3.2%1.73M after2 lots
Mar 31, 2026 (view filing)Mar 31Same dayLu HongboDirectorPPurchase+75.0K$20.00+$1.50M+21.6%423.0K after
Feb 13, 2026 (view filing)Feb 112 daysLu HongboDirectorPPurchase+26.0K$22.50+$584.7K+8.1%348.0K after
Feb 13, 2026 (view filing)Feb 12-131 dayAllen Patricia LDirectorPPurchase+19.9K$25.16+$499.7KNew position19.9K after4 lots
Feb 3, 2026 (view filing)Feb 21 dayMoulder Leon O JrChief Executive OfficerPPurchase+57.0K$17.96+$1.02M+15.6%423.2K after
Jan 9, 2026 (view filing)Jan 7-92 daysMoulder Leon O JrChief Executive OfficerPPurchase+100.0K$16.39+$1.64M+37.6%366.2K after3 lots
Oct 14, 2025 (view filing)5:14 PM ETOct 95 daysGeorge Simeon and 1 other10% OwnerPPurchase+126.3K$19.00+$2.40M+7.1%1.92M after2 lots
Oct 14, 2025 (view filing)Oct 95 daysNunn Jason RaleighDirectorPPurchase+63.2K$19.00+$1.20M+5.7%1.17M after
Oct 14, 2025 (view filing)Oct 95 daysEnright Patrick GDirectorPPurchase+105.3K$19.00+$2.00M+6.1%1.83M after
Oct 14, 2025 (view filing)Oct 95 daysEnright Patrick GDirectorPPurchase+12.0K$20.85+$250.0KNew position12.0K after
Oct 9, 2025 (view filing)4:15 PM ETOct 72 daysHarwin Peter Evan and 3 othersDirectorPPurchase+316.2K$19.00+$6.01M+16.7%2.21M after
Oct 9, 2025 (view filing)Oct 72 daysMoulder Leon O JrSee RemarksPPurchase+36.9K$20.85+$769.9KNew position36.9K after
Oct 9, 2025 (view filing)Sep 13, 2024-Oct 7, 2025391 daysLateLu HongboDirectorPPurchase+322.0K$18.63+$6.00MNew position322.0K after2 lots
Apr 28, 2025 (view filing)Feb 780 daysXiao TingDirectorPPurchase+10.0K$7.76+$77.6KNew position10.0K afterAmended
Feb 19, 2025 (view filing)Feb 181 dayMoulder Leon O JrChief Executive OfficerPPurchase+25.0K$6.67+$166.8K+10.4%266.2K after
Dec 4, 2024 (view filing)Dec 3-41 dayMoulder Leon O JrChief Executive OfficerPPurchase+70.0K$10.26+$718.1K+40.9%241.2K after2 lots
Nov 20, 2024 (view filing)Nov 18-192 daysMoulder Leon O JrChief Executive OfficerPPurchase+10.0K$14.89+$148.9K+6.2%171.2K after2 lots
Sep 20, 2024 (view filing)Sep 18-202 daysMoulder Leon O JrChief Executive OfficerPPurchase+20.0K$18.04+$360.8K+1.2%1.67M after4 lots
Sep 18, 2024 (view filing)4:15 PM ETSep 162 daysEnavate Sciences GP, LLC and 1 other10% OwnerPPurchase+882.4K$17.00+$15.0M+30.6%3.76M after
Sep 17, 2024 (view filing)8:56 PM ETSep 161 dayHarwin Peter Evan and 3 othersDirectorPPurchase+300.0K$17.00+$5.10M+18.8%1.89M afterAmended
Sep 17, 2024 (view filing)Sep 134 daysLu HongboDirectorPPurchase+58.8K$17.00+$1.00MNew position58.8K after
Sep 16, 2024 (view filing)8:51 PM ETSep 16Same dayGeorge Simeon and 1 other10% OwnerPPurchase+2.24M$17.00+$38.0MNew position1.11M after3 lots
Sep 16, 2024 (view filing)Sep 16Same dayEnright Patrick GDirectorPPurchase+440.0K$17.00+$7.48M+131.5%774.5K after
Sep 16, 2024 (view filing)Sep 16Same dayNunn Jason RaleighDirectorPPurchase+882.4K$17.00+$15.0M+387.2%1.11M after2 lots